Poolbeg Pharma PLC (POLB.L) Stock
Poolbeg Pharma PLC

Company profile
Poolbeg Pharma reports about 15 full-time employees.
Figures from company filings; latest fiscal year ended December 31, 2024.
About Poolbeg Pharma PLC
Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, engages in developing immunotherapy for cancer in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome; and phase 2 for the treatment of influenza. It also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; and AI program, a novel drug discovery therapies for the treatment of influenza and respiratory syncytial viruses. Poolbeg Pharma plc was incorporated in 2021 and is based in London, United Kingdom.
Largest shareholders
- Cathal Friel5.378 %5.38%
- Hargreaves Lansdown Fund Managers Ltd.3.48%
- Schroder Investment Management Ltd.3.27%
- IG Markets Ltd.2.90%
- HSBC Bank Plc (Market-Maker)1.42%
Share of the company, as of September 25, 2026
Leadership
- Jeremy Skillington Ph.D. — CEO & Director, 54
- Cathal Martin Friel — Executive Chairman of The Board, 61
- Ian O'Connell — CFO & Director, 38
- Carol Dalton — Vice President of Investor Relations & Public Relations
- Liam Tremble — Principal Scientist
What companies are similar to Poolbeg Pharma?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include International Biotechnology Ord (IBT.L), Beximco Pharmaceuticals Limited (BXP.L), Venture Life Group plc (VLG.L), Hellenic Dynamics Plc (HELD.L).
Company Information
Data as of .
How to cite: DataPorium, “Poolbeg Pharma PLC (POLB.L)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/POLB.L